Cyanine7.5 hydrazide

Cat. # Quantity Price Lead time
16070 1 mg $110.00 in stock
26070 5 mg $210.00 in stock
46070 25 mg $410.00 in stock
56070 50 mg $695.00 in stock
66070 100 mg $1190.00 in stock

A carbonyl-reactive hydrazide derivative of Cyanine7.5 near infrared (NIR) fluorophore. This dye has similar spectral properties with ICG (indocyanine green), but has a higher quantum yield of fluorescence. Hence, this fluorophore is ideal for in vivo imaging.

This is a carbonyl-reactive dye which is particularly useful for the labeling of antibodies after periodate oxidation. It also labels other carbonyl compounds (aldehydes and ketones), for example, many saccharides.

Cyanine7.5 absorbance and emission spectra

Cyanine7.5 absorbance and emission spectra

Customers also purchased with this product

Sulfo-Cyanine7 NHS ester

Sulfo-Cyanine7 NHS ester is a water soluble, near infrared, amine-reactive dye.

Cyanine5.5 hydrazide

Cyanine5.5 hydrazide is a carbonyl reactive NIR dye which is particularly suitable for the labeling of periodate oxidized glycoproteins, i.e. antibodies.

TAMRA hydrazide, 6-isomer

6-TAMRA azide is a carbonyl reactive hydrazide derivative of tetramethylrhodamine (TAMRA) fluorophore.

General properties

Appearance: green powder
Mass spec M+ increment: 644.4
Molecular weight: 735.82
Molecular formula: C45H52Cl2N4O
Solubility: moderate solubility in water, good in polar organic solvents (DMF, DMSO, alcohols)
Quality control: NMR 1H, HPLC-MS (95%)
Storage conditions: Storage: 24 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. Avoid prolonged exposure to light. Desiccate.
MSDS: Download
Product specifications

Spectral properties

Excitation maximum, nm: 788
ε, L⋅mol−1⋅cm−1: 223000
Emission maximum, nm: 808

Product citations

  1. Liu, S.; Dozois, M.D.; Chang, C.N.; Ahmad, A.; Ng, D.L.T.; Hileeto, D.; Liang, H.; Reyad, M.-M.; Boyd, S.; Jones, L.W.; Gu, F.X. Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage. Molecular Pharmaceutics, 2016, 13(9), 2897–2905. doi: 10.1021/acs.molpharmaceut.6b00445
Your item has been added. View your cart or proceed to checkout
The count of items is incorrect.